About this trial
This trial studies how well a medicine called abemaciclib works for patients with ovarian or endometrial cancer that has come back. The goal is to see if abemaciclib can stop cancer cells from growing by blocking certain enzymes. Researchers want to find out how effective and safe this treatment is for these types of cancer.
This is a Phase 2 trial, which means it is looking at how well the treatment works and its safety. The trial is FDA-regulated and plans to include about 32 participants.
Who can join
Women aged 18 and older with a confirmed diagnosis of recurrent ovarian or endometrial cancer can join. They must have had at least one prior chemotherapy treatment. Participants should be able to swallow pills and will need to meet certain health criteria, which the trial team will confirm.
Conditions
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
The study team makes the final call on eligibility.
What happens in the study
Everyone in the trial will take abemaciclib by mouth twice a day for 28 days. If their tumors are hormone receptor positive, they will also take either anastrozole or letrozole. The treatment cycles will repeat every 28 days unless there is disease progression or unacceptable side effects.
Where
This trial is running at 1 location in the United States. It is currently recruiting.
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California